{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T04:49:29Z","timestamp":1762490969564,"version":"build-2065373602"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.lungcan.2025.108768","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T01:51:40Z","timestamp":1758765100000},"page":"108768","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Evaluating docetaxel effectiveness in KRAS G12C-mutated NSCLC: insights from a Real-World cohort"],"prefix":"10.1016","volume":"209","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9031-1368","authenticated-orcid":false,"given":"Matthias","family":"Scheffler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8554-3933","authenticated-orcid":false,"given":"Lia","family":"Tzala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karly","family":"Louie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thorsten","family":"Persigehl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3254-4809","authenticated-orcid":false,"given":"Simon","family":"Lennartz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarina","family":"\u00d6hrling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4101-5458","authenticated-orcid":false,"given":"Julia","family":"Gehrman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3390-0411","authenticated-orcid":false,"given":"Lea","family":"Ruge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"John","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Rasokat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3047-6486","authenticated-orcid":false,"given":"Anna","family":"Kron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michaela","family":"Potzner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0312-5760","authenticated-orcid":false,"given":"Sabine","family":"Merkelbach-Bruse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8806-4786","authenticated-orcid":false,"given":"Reinhard","family":"Buettner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Udo","family":"Siebolts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2025.108768_b0005","doi-asserted-by":"crossref","unstructured":"The Clinical Lung Cancer Genome Project (CLCGP) and Network Genomic Medicine (NGM),. A Genomics-Based Classification of Human Lung Tumors. Sci Transl Med. October 30, 2013 [cited March 31, 2022];5(209). Available at: https:\/\/www.science.org\/doi\/10.1126\/scitranslmed.3006802.","DOI":"10.1126\/scitranslmed.3006802"},{"issue":"7","key":"10.1016\/j.lungcan.2025.108768_b0010","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1007\/s00108-022-01372-2","article-title":"Zielgerichtete Therapie des nichtkleinzelligen Lungenkarzinoms","volume":"63","author":"Scheffler","year":"2022","journal-title":"Innere Medizin."},{"issue":"2","key":"10.1016\/j.lungcan.2025.108768_b0015","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMoa011954","article-title":"Comparison of four Chemotherapy Regimens for Advanced Non\u2013Small-Cell Lung Cancer","volume":"346","author":"Schiller","year":"2002","journal-title":"N Engl J Med. January 10"},{"key":"10.1016\/j.lungcan.2025.108768_b0020","doi-asserted-by":"crossref","unstructured":"Solomon BJ, Liu G, Felip E, Mok TSK, Soo RA, Mazieres J, et al. Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non\u2013Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study. JCO. May 31, 2024;JCO.24.00581.","DOI":"10.1200\/JCO.24.00581"},{"key":"10.1016\/j.lungcan.2025.108768_b0025","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.lungcan.2021.07.005","article-title":"On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma","volume":"160","author":"Lindsay","year":"2021","journal-title":"Lung Cancer"},{"issue":"13","key":"10.1016\/j.lungcan.2025.108768_b0030","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","article-title":"KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors","volume":"383","author":"Hong","year":"2020","journal-title":"N Engl J Med. September 24"},{"issue":"25","key":"10.1016\/j.lungcan.2025.108768_b0035","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for Lung Cancers with KRAS p","volume":"384","author":"Skoulidis","year":"2021","journal-title":"G12C Mutation. N Engl J Med. June 24"},{"issue":"4","key":"10.1016\/j.lungcan.2025.108768_b0040","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jtho.2018.12.013","article-title":"K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways","volume":"14","author":"Scheffler","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2025.108768_b0045","doi-asserted-by":"crossref","unstructured":"Cook JH, Melloni GEM, Gulhan DC, Park PJ, Haigis KM. The origins and genetic interactions of KRAS mutations are allele- and tissue-specific. Nat Commun. March 22, 2021;12(1):1808.","DOI":"10.1038\/s41467-021-22125-z"},{"issue":"7477","key":"10.1016\/j.lungcan.2025.108768_b0050","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nature12796","article-title":"K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions","volume":"503","author":"Ostrem","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.lungcan.2025.108768_b0055","doi-asserted-by":"crossref","unstructured":"De Langen AJ, Johnson ML, Mazieres J, Dingemans A-MC, Mountzios G, Pless M, et al. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial. The Lancet. March 2023;401(10378):733\u2013746.","DOI":"10.1016\/S0140-6736(23)00221-0"},{"key":"10.1016\/j.lungcan.2025.108768_b0060","doi-asserted-by":"crossref","unstructured":"Mok TSK, Yao W, Duruisseaux M, Doucet L, Azk\u00e1rate Mart\u00ednez A, Gregorc V, et al. KRYSTAL-12: Phase 3 study of adagrasib versus docetaxel in patients with previously treated advanced\/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation. JCO. June 10, 2024;42(17_suppl):LBA8509\u2013LBA8509.","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA8509"},{"issue":"2","key":"10.1016\/j.lungcan.2025.108768_b0065","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S1470-2045(13)70586-2","article-title":"Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial","volume":"15","author":"Reck","year":"2014","journal-title":"Lancet Oncol."},{"issue":"9944","key":"10.1016\/j.lungcan.2025.108768_b0070","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(14)60845-X","article-title":"Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial","volume":"384","author":"Garon","year":"2014","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.lungcan.2025.108768_b0075","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1158\/2159-8290.CD-22-1420","article-title":"Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC","volume":"13","author":"Negrao","year":"2023","journal-title":"Cancer Discovery. July 7"},{"issue":"30","key":"10.1016\/j.lungcan.2025.108768_b0085","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.2217\/fon-2021-0424","article-title":"Real-World Efficacy of Docetaxel Plus Nintedanib after Chemo-Immunotherapy failure in Advanced Pulmonary Adenocarcinoma","volume":"17","author":"Metzenmacher","year":"2021","journal-title":"Future Oncol."},{"issue":"7855","key":"10.1016\/j.lungcan.2025.108768_b0090","first-page":"629","article-title":"Evaluating eligibility criteria of oncology trials using real-world data and AI","volume":"592","author":"Liu","year":"2021","journal-title":"Nature. April 22"},{"issue":"3","key":"10.1016\/j.lungcan.2025.108768_b0095","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jtho.2021.10.013","article-title":"Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma is Affected by KRAS Mutation Status","volume":"17","author":"Ricciuti","year":"2022","journal-title":"J. Thorac. Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2025.108768_b0100","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.jtho.2024.03.002","article-title":"Precision Immunotherapy for STK11\/KEAP1-Mutant NSCLC","volume":"19","author":"Ricciuti","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2025.108768_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanepe.2023.100788","article-title":"Evaluation of the effectiveness of a nationwide precision medicine program for patients with advanced non-small cell lung cancer in Germany: a historical cohort analysis","volume":"36","author":"K\u00e4stner","year":"2024","journal-title":"The Lancet Regional Health - Europe."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225006609?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225006609?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T04:46:04Z","timestamp":1762490764000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500225006609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":20,"alternative-id":["S0169500225006609"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108768","relation":{},"ISSN":["0169-5002"],"issn-type":[{"type":"print","value":"0169-5002"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluating docetaxel effectiveness in KRAS G12C-mutated NSCLC: insights from a Real-World cohort","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108768","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"108768"}}